Edesa Biotech, Inc. (EDSA)
EDSANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.25
+0.1107 (+5.17%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $33.62m
- P/E
- –
- EPS, last 4 quarters
- $-1.69
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.7200 to $20.32
- Average volume
- 42.0k
- Previous close
- $2.14
Earnings
next estimate $-0.5700Next report Dec 11, 2026
Sep 2025
-18.5%
Dec 2025
0.0%
Mar 2026
-104.2%
Jun 2026
-36.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.47m | -$2.34m | -$4.30m | -$5.52m |
| Net income | -$2.23m | -$2.25m | -$4.22m | -$5.41m |
News
8 latest- Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain RTTNews · 7 hours ago
- Edesa Biotech, Inc. Enters Into Collaboration and License Agreement with Kyorin Pharmaceutical and Terminates ATM AgreementFintel · 14 hours ago
- Edesa Biotech Partners With KYORIN In Japan Deal Worth Up To $140 Million Plus Royalties; Stock Up RTTNews · 15 hours ago
- Edesa Biotech, Inc. Approves Executive Salary Increases Retroactive to July 1, 2026Fintel · Oct 23, 2026
- Edesa Secures FDA Clearance To Expand Phase 2 Vitiligo Trial Of EB06 Into U.S RTTNews · Oct 15, 2026
- Edesa Biotech Prices $25 Mln Public Offering Of Shares And Warrants; Stock Down RTTNews · Aug 20, 2026
- Edesa Biotech Announces Proposed Public Offering; Stock Down RTTNews · Aug 19, 2026
- After-Hours Biotech Gainers: TNON, BIVI, EDSA, RNAZ, HCWB RTTNews · Aug 18, 2026
The company
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The Company's most advanced Respiratory drug candidate is paridiprubart, which is being developed as a potential treatment for Acute Respiratory Distress Syndrome, a life-threatening form of respiratory failure.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- edesabiotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.